NCT03978702 (IMMUNOPANC) is a NA clinical trial of Blood sampling in Pancreas Cancer, sponsored by Institut Paoli-Calmettes.

Who is sponsoring NCT03978702?

NCT03978702 is sponsored by Institut Paoli-Calmettes.

What drugs are being tested in NCT03978702?

Interventions in NCT03978702: Blood sampling.

What condition does NCT03978702 study?

NCT03978702 studies Pancreas Cancer, Pancreatectomy; Hyperglycemia.

Is NCT03978702 still recruiting?

NCT03978702 is currently status unknown. Last updated 6 January 2022.

Last reviewed 2022-01-06 · How we verify

NCT03978702: IMMUNOPANC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Impact of Pancreatectomy on Systemic Immunity

Status unknown NA Last updated 6 January 2022

What this trial tests

NA trial testing Blood sampling in Pancreas Cancer in 40 participants. Status unknown.

Timeline

24 February 2021

Primary endpoint
27 July 2022

27 July 2022

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	24 February 2021
Primary completion	27 July 2022
Estimated completion	27 July 2022
Sites	1 location across France

Drugs / interventions tested

Blood sampling — full drug profile →

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →
Pancreatectomy; Hyperglycemia — all drugs for Pancreatectomy; Hyperglycemia →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

18 and older, any sex, with Pancreas Cancer or Pancreatectomy; Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims at establishing the profile of the immune reaction that occurs in the early surgical suites after pancreatectomy. Blood samples will be collected before surgery, (Day-1), at day0, and after surgery at Day 1, Day 3, Day 7 at 1 year after pancreatectomy. Mass cytometry, genomic and transcriptomic approaches will be used to evaluate the immune systemic modulation after surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Preoperative lymphocyte signature predicts pancreatic fistula after pancreatoduodenectomy.
Garnier J, Bellan G, Palen A, Durand X, et al · · 2026 · PMID 41673079 · DOI 10.1038/s43856-026-01422-y
Immediate variations in high-dimensional circulating immune cells following pancreatectomy.
Garnier J, Palen A, Durand X, Ewald J, et al · · 2025 · PMID 41255738 · DOI 10.1002/cti2.70059
Preoperative Lymphocyte Signature Predicts Pancreatic Fistula After Pancreatoduodenectomy
Garnier J, Bellan G, Palen A, Durand X, et al · · 2025 · DOI 10.21203/rs.3.rs-5219663/v1

Verify or expand the search:

Other trials of Blood sampling

Trials testing the same drug.

NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
NCT07237984 — Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway · not yet recruiting
NCT06544018 — Circadian Rhythm Deregulation in Patients With CAPS · NA · recruiting
NCT07245550 — Thyroid and Adrenal Disorders in ICU · not yet recruiting
NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03978702 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 6 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03978702.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing